AMNEAL PHARMACEUTICALS, INC. Total Long-Term Debt
AMNEAL PHARMACEUTICALS, INC. (AMRX) had Total Long-Term Debt of $2.57 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2026-08-06
- 2026-06-30: Long-term Debt $2.57B.
- 2026-03-31: Long-term Debt $2.57B.
- 2025-12-31: Long-term Debt $2.57B.
- 2025-09-30: Long-term Debt $2.57B.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $2.57B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.57B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.57B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $2.57B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.18B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.19B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.39B 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.39B 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.40B 10-Q · filed 2024-08-09 |
| 2024-03-31 | $2.41B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.42B 10-K · filed 2025-02-28 |
| 2023-09-30 | $2.57B 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.58B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $2.59B 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.62B 10-K · filed 2024-03-14 |
| 2022-09-30 | $2.64B 10-Q · filed 2022-11-07 |
| 2022-06-30 | $2.65B 10-Q · filed 2022-08-08 |
| 2021-12-31 | $2.71B 10-K · filed 2023-03-03 |
| 2020-12-31 | $2.78B 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.79B 10-Q · filed 2020-11-06 |
| 2020-06-30 | $2.79B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.80B 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.63B 10-K · filed 2021-03-01 |
| 2018-12-31 | $2.65B 10-K · filed 2020-03-02 |
| 2018-06-30 | $2.66B 10-Q · filed 2018-08-09 |
| 2017-12-31 | $1.44B 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |